BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. Am J Respir Crit Care Med 2019;199:1195-204. [DOI: 10.1164/rccm.201810-1860so] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Szalontai K, Gémes N, Furák J, Varga T, Neuperger P, Balog JÁ, Puskás LG, Szebeni GJ. Chronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer. J Clin Med 2021;10:2889. [PMID: 34209651 DOI: 10.3390/jcm10132889] [Reference Citation Analysis]
2 Serban KA, Pratte KA, Bowler RP. Protein Biomarkers for COPD Outcomes. Chest 2021;159:2244-53. [PMID: 33434499 DOI: 10.1016/j.chest.2021.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Dai G, Ran Y, Wang J, Chen X, Peng J, Li X, Deng H, Xiao M, Zhu T. Clinical Differences between Eosinophilic and Noneosinophilic Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study. Mediators Inflamm 2020;2020:1059079. [PMID: 33273887 DOI: 10.1155/2020/1059079] [Reference Citation Analysis]
4 Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, Martinez FJ, Miller BE, Wise R, Zhu CQ, Lomas D. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res 2021;22:130. [PMID: 33910578 DOI: 10.1186/s12931-021-01706-y] [Reference Citation Analysis]
5 Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, Wells JM, Couper DJ, Labaki WW, Curtis JL, Han MK, Paine R 3rd, Woodruff PG, Criner GJ, Hansel NN, Diaz I, Ballman KV, Nakahira K, Choi ME, Martinez FJ, Choi AMK, Cloonan SM. Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. Respir Res 2021;22:126. [PMID: 33902556 DOI: 10.1186/s12931-021-01707-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang HH, Cheng SL. From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease. Biomedicines 2021;9:1638. [PMID: 34829866 DOI: 10.3390/biomedicines9111638] [Reference Citation Analysis]
7 Uzeloto JS, de Toledo-Arruda AC, Silva BSA, Golim MA, Braz AMM, de Lima FF, Grigoletto I, Ramos EMC. Systemic Cytokine Profiles of CD4+ T Lymphocytes Correlate with Clinical Features and Functional Status in Stable COPD. Int J Chron Obstruct Pulmon Dis 2020;15:2931-40. [PMID: 33223825 DOI: 10.2147/COPD.S268955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Bui DS, Agusti A, Walters H, Lodge C, Perret JL, Lowe A, Bowatte G, Cassim R, Hamilton GS, Frith P, James A, Thomas PS, Jarvis D, Abramson MJ, Faner R, Dharmage SC. Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study. ERJ Open Res 2021;7:00020-2021. [PMID: 34527727 DOI: 10.1183/23120541.00020-2021] [Reference Citation Analysis]
9 Pouwels SD, Klont F, Bischoff R, Ten Hacken NHT. Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2019;200:114. [PMID: 30888832 DOI: 10.1164/rccm.201902-0356LE] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Singh D, Lea S, Mathioudakis AG. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs 2021;81:1821-30. [PMID: 34731461 DOI: 10.1007/s40265-021-01616-9] [Reference Citation Analysis]
11 Andreeva E, Pokhasnikova M, Lebedev A, Moiseeva I, Kozlov A, Kuznetsova O, Degryse JM. Inflammatory parameters and pulmonary biomarkers in smokers with and without chronic obstructive pulmonary disease (COPD). J Thorac Dis 2021;13:4812-29. [PMID: 34527321 DOI: 10.21037/jtd-20-1580] [Reference Citation Analysis]
12 Singh D, Bafadhel M, Brightling CE, Sciurba FC, Curtis JL, Martinez FJ, Pasquale CB, Merrill DD, Metzdorf N, Petruzzelli S, Tal-Singer R, Compton C, Rennard S, Martin UJ. Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020;202:660-71. [PMID: 32186896 DOI: 10.1164/rccm.201912-2384PP] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
13 Alobaidi NY, Stockley JA, Stockley RA, Sapey E. An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways' function guide diagnosis and management? Ann Thorac Med 2020;15:54-63. [PMID: 32489439 DOI: 10.4103/atm.ATM_323_19] [Reference Citation Analysis]
14 Celli B, Locantore N, Yates JC, Bakke P, Calverley PMA, Crim C, Coxson HO, Lomas DA, MacNee W, Miller BE, Mullerova H, Rennard SI, Silverman EK, Wouters E, Tal-Singer R, Agusti A, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. Eur Respir J 2021;57:2001339. [PMID: 33303557 DOI: 10.1183/13993003.01339-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zuur-Telgen MC, Citgez E, Zuur AT, VanderValk P, van der Palen J, Kerstjens HAM, Brusse-Keizer M. Predicting Mortality in COPD with Validated and Sensitive Biomarkers; Fibrinogen and Mid-Range-Proadrenomedullin (MR-proADM). COPD 2021;:1-7. [PMID: 34886719 DOI: 10.1080/15412555.2021.2009791] [Reference Citation Analysis]
16 Stockley RA. COPD frequent exacerbators: time for the recycle bin? Eur Respir J 2021;57:2003758. [PMID: 33574050 DOI: 10.1183/13993003.03758-2020] [Reference Citation Analysis]
17 Beech A, Lea S, Li J, Jackson N, Mulvanny A, Singh D. Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes. Biomedicines 2021;9:1337. [PMID: 34680454 DOI: 10.3390/biomedicines9101337] [Reference Citation Analysis]
18 Koba T, Takeda Y, Narumi R, Shiromizu T, Nojima Y, Ito M, Kuroyama M, Futami Y, Takimoto T, Matsuki T, Edahiro R, Nojima S, Hayama Y, Fukushima K, Hirata H, Koyama S, Iwahori K, Nagatomo I, Suzuki M, Shirai Y, Murakami T, Nakanishi K, Nakatani T, Suga Y, Miyake K, Shiroyama T, Kida H, Sasaki T, Ueda K, Mizuguchi K, Adachi J, Tomonaga T, Kumanogoh A. Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres. ERJ Open Res 2021;7:00658-2020. [PMID: 33778046 DOI: 10.1183/23120541.00658-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, Wells JM, Hastie AT, Labaki WW, Cooper CB, Comellas AP, Criner GJ, Krishnan JA, Paine R 3rd, Hansel NN, Bowler RP, Barr RG, Peters SP, Woodruff PG, Curtis JL, Han MK, Ballman KV, Martinez FJ, Choi AM, Nakahira K, Cloonan SM, Choi ME; SPIROMICS Investigators. Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. JCI Insight 2020;5:133984. [PMID: 31895696 DOI: 10.1172/jci.insight.133984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
20 Cazzola M, Puxeddu E, Ora J, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Mol Diagn Ther 2019;23:603-14. [PMID: 31363933 DOI: 10.1007/s40291-019-00413-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Yip KP, Stockley RA, Sapey E. Catching "Early" COPD - The Diagnostic Conundrum. Int J Chron Obstruct Pulmon Dis 2021;16:957-68. [PMID: 33880020 DOI: 10.2147/COPD.S296842] [Reference Citation Analysis]
22 Li S, Zhao S, Wu Z, Wang F, Li W. Alteration of immune profiles is associated with pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Mol Med Rep 2021;24:742. [PMID: 34435653 DOI: 10.3892/mmr.2021.12382] [Reference Citation Analysis]
23 Deng M, Yin Y, Zhang Q, Zhou X, Hou G. Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis. Front Immunol 2021;12:670971. [PMID: 34093570 DOI: 10.3389/fimmu.2021.670971] [Reference Citation Analysis]